Codexis, Inc. (CDXS) Stock
NSQ · CDXS
1.36
Fundamentals
Market cap
$148.93M
Price / Earnings ratio
-4.7x
Price / Sales ratio
1.9x
Price / Book ratio
4.4x
Return on assets
-0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Codexis, Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
SectorHealthcare
IndustryBiotechnology
Employees146
CEODr. Alison Moore Ph.D.
IPO DateApr 22, 2010
HeadquartersRedwood City, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Alison Moore Ph.D. | President, CEO & Director | 1967 |
| Ms. Georgia L. Erbez | CFO & Chief Business Officer | 1967 |
| Dr. Stefan Lutz Ph.D. | Chief Scientific Officer | — |
| Mr. Britton Jimenez | Senior Vice President of Sales & Marketing | — |
| Ms. Karen Frechou-Armijo | Senior VP & Head of Human Resources | — |
| Mr. John Schiffhauer | Senior Vice President of Intellectual Property | — |
Fundamentals
Valuation
Market cap$148.93M
Price-to-sales ratio1.86
Price-to-book value4.38
Price-earnings ratio-4.70
Return on Equity-68.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio13.53
Earnings Per Share
Earnings Per Share$-0.33
Income Statement
Average volume909,473
EBITDA$-18.15M
1 year high (52w)$2.98
1 year low (52w)$0.96
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



